Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205651 | 0.76 | MAPT (0.46) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2614903 | 0.75 | KDM4E (0.58) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28570620 | 0.73 | MAPT (0.46) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1635786 | 0.73 | MAPT (0.54) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3494874 | 0.72 | MAPT (0.44) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4477605 | 0.72 | RAB9A (0.61) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9042363 | 0.71 | RAB9A (0.63) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28560105 | 0.69 | MAPT (0.44) | NPC1ALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL306543 | 0.67 | MAPT (0.50) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29631752 | 0.67 | MAPT (0.50) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932050-B2 | Enzymatic substrates derived from phenoxazinone and their use as developers in detection of microorganisms with peptidase activity | BIOMERIEUX (FR) | 2011-04-26 | — | — | US | disclosed |
| US-20100028926-A1 | Novel enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity | BIOMERIEUX (FR) | 2010-02-04 | — | — | US | disclosed |
| US-7626018-B2 | Enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity | bioMérieux (FR) | 2009-12-01 | — | — | US | disclosed |
| US-20080293094-A1 | Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity | BIOMERIEUX (FR) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293094-A1 | Novel Enzymatic Substrates Derived from Phenoxazinone and Their Use as Developer in Detection of Microorganisms with Peptidase Activity | PEPD, CTRL, PREP | RAB9A 4572/4885NPC1 4351/4885ALDH1A1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.